Incretin-based therapies for obesity treatment

Aline Haas De Mello, Morgana Prá, Larissa Colonetti Cardoso, Rosiane De Bona Schraiber, Gislaine Tezza Rezin

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.

Original languageEnglish (US)
Pages (from-to)967-981
Number of pages15
JournalMetabolism: Clinical and Experimental
Issue number9
StatePublished - Sep 1 2015
Externally publishedYes


  • DPP-4
  • GLP-1
  • Incretin
  • Obesity
  • Treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Incretin-based therapies for obesity treatment'. Together they form a unique fingerprint.

Cite this